Stock & Company Details
Akebia Therapeutics Inc. $AKBA
Price:
N/A
N/A
277M
$212M
52 Week High:
N/A
10 Day Average Volume:
N/A
-6.69
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
AKBA technical indicators
Latest Akebia Therapeutics Inc. (AKBA) indicator readings as of 2026-10-29.
AKBA's 14-day RSI is 48.3, in neutral territory. At $0.74 it is trading 35.5% below its 200-day moving average of $1.15, and below its 50-day average of $0.85. Price sits in the middle of its Bollinger Bands ($0.52 to $0.94). ADX reads 30.2, indicating a trending market.
Overview
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.
Finance Bot
Ask your questions
Start by typing a question below.
